Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET
Company Participants
Susan Mesco - Head of Investor Relations
Frank Lee - CEO & Director
Charles Reinhart - Chief Financial Officer
Tony Molloy - Chief Legal & Compliance Officer
Conference Call Participants
Gregory Renza - RBC Capital Markets
David Amsellem - Piper Sandler
Glen Santangelo - Jefferies
Gary Nachman - Raymond James
Hardik Parikh - J. P. Morgan
Leszek Sulewski - Truist Securities
Serge Belanger - Needham & Co.
Balaji Prasad - Barclays
Operator
Good day. And thank you for standing by. Welcome to the Q2 2024 Pacira BioSciences Earnings Conference Call. All lines have been placed on mute to prevent any background noise. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the call over to your speaker today, Susan Mesco, Head of Investor Relations. Please go ahead.
Susan Mesco
Thank you and good afternoon, everyone. Welcome to today's conference call to discuss our second quarter 2024 financial results. Joining me are Frank Lee, Chief Executive Officer, Tony Molloy, Chief Legal Counsel and Charles Reinhart, Chief Financial Officer. Jonathan Slonin, Chief Medical Officer is also here for today's question-and-answer session.
Before we begin, let me remind you that this call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties. For information concerning risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or the Pacira website.
With that, I will now turn the call over to Frank Lee.
Frank Lee
Thank you, Susan, and good afternoon, everyone. As our top priority for 2024 is to ensure we're ready to accelerate growth next year and beyond. Toward that end, the first half of the year was marked by strong execution and meaningful progress towards our commercial, clinical, and business objectives. We maintain solid sales across all three of our products, strengthened our balance sheet, and bolstered our leadership team. We reshaped our corporate culture and enhanced our organization with new talent and capabilities. The foundation for a modernized commercial medical market access organization is now in place. Looking ahead to the remainder of the year, we continue to invest in the organization and set the stage for strong sustainable top line growth in 2025 and beyond.